Drug Profile

Research programme: RNA targeted small molecules - Arrakis Therapeutics

Alternative Names: Research programme: Myotonic dystrophy therapeutics - Arrakis Therapeutics

Latest Information Update: 14 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Dec 2024 Preclinical trials in Myotonic dystrophy in USA (unspecified route)
04 Dec 2024 Pharmacodynamics data from preclinical trials in Myotonic dystrophy released by Arrakis Therapeutics
08 Apr 2020 Roche in-licenses RNA-targeted small molecule drug technology from Arrakis Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com